HBV-IN-10

HBV-IN-10 is an isomer of compound 6 (WO2021204258A1). Compound 6 is a potent inhibitor of hepatitis B surface antigen (HBsAg) (0.1 μM < EC50 ≤ 1 μM).

(5S,8R)-HBV-IN-10, an isomer of compound 6 (WO2021204258A1), is a potent inhibitor of hepatitis B surface antigen (HBsAg) with an EC50 range of 0.1 μM to 1 μM.

HBV-IN-37 is an HBV inhibitor with an EC50 value of 10 μM and can be used for hepatitis B disease-related research.

Helioxanthin 8-1, an analogue of helioxanthin, exhibits significant in vitro anti-HBV/HCV/HSV-1/HIV activity with EC50 of >5/10/1.4/15 μM.

HBV-IN-9 (example 20) is a potent inhibitor of HBsAg (HBV surface antigen) with an IC50 of 10 nM and also inhibits HBV DNA replication with an IC50 of 0.15 nM.

12-Bromododecanoic acid, a halogenated derivative of lauric acid, serves in the synthesis of clickable myristic acid derivatives and functions as a model fatty acid ligand for elucidating the X-ray crystal structure of bovine β-lactoglobulin-ligand complexes. This compound, at a concentration of 10 µg/ml, has been shown to diminish virion DNA in the culture supernatant of primary hepatocytes from a duckling model of hepatitis B virus (HBV) infection and exhibits inhibitory activity against HIV replication in CEM-SS T cells with an EC50 value of 38 µM.